|
Peptide KRWIILGLNK is a well-established epitope derived from the HIV-1 Gag protein (p24) and recognized in the context of HLA-B*2705 for CD8⁺ T-cell responses.
Peptide Sequence: KRWIILGLNK (H-KRWIILGLNK-OH)
Source: HIV-1 Gag polyprotein (p24 region, residues 263–272)
HLA Restriction: HLA-B*2705 (MHC class I)
Applications: Used in T-cell stimulation assays (e.g., ELISPOT, ICS, cytotoxicity, proliferation) to assess CD8⁺ T-cell immune responses against HIV.
Features & Benefits:
- Immunogenic Epitope Analogue:
KRWIILGLNF analog functions as an HLA-B*2705–restricted CD8⁺ T-cell epitope, analogous to the established KRWIILGLNK peptide.
- Functional Use in Immunoassays:
Effective for stimulating antigen-specific CD8⁺ T cells in various assays—such as ELISPOT, intracellular cytokine staining, cytotoxicity assays, or proliferation tests.
- T-Cell Activation Studies:
Can be utilized to challenge and characterize HLA-B*2705–restricted T-cell populations in PBMCs or splenocytes.
- Variant Exploration:
Useful for studying the immunological impact of substituting lysine (“K”) with phenylalanine (“F”)—potentially affecting peptide–MHC binding or TCR recognition.
- Vaccine & Immunotherapy Research:
May serve as a comparative peptide in vaccine design, immunogenicity screening, or T-cell receptor (TCR) fine-mapping efforts.
|
